468 related articles for article (PubMed ID: 33152916)
1. Male predisposition to severe COVID-19: Review of evidence and potential therapeutic prospects.
Acheampong DO; Barffour IK; Boye A; Aninagyei E; Ocansey S; Morna MT
Biomed Pharmacother; 2020 Nov; 131():110748. PubMed ID: 33152916
[TBL] [Abstract][Full Text] [Related]
2. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
Cadegiani FA; Goren A; Wambier CG
Med Hypotheses; 2020 Oct; 143():110112. PubMed ID: 32721806
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor.
Mjaess G; Karam A; Aoun F; Albisinni S; Roumeguère T
Prog Urol; 2020 Sep; 30(10):484-487. PubMed ID: 32620366
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?
Gemmati D; Bramanti B; Serino ML; Secchiero P; Zauli G; Tisato V
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32423094
[TBL] [Abstract][Full Text] [Related]
5. Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer.
Chakravarty D; Nair SS; Hammouda N; Ratnani P; Gharib Y; Wagaskar V; Mohamed N; Lundon D; Dovey Z; Kyprianou N; Tewari AK
Commun Biol; 2020 Jul; 3(1):374. PubMed ID: 32641750
[TBL] [Abstract][Full Text] [Related]
6. Cross-Talk Between Key Players in Patients with COVID-19 and Ischemic Stroke: A Review on Neurobiological Insight of the Pandemic.
Kaushik P; Kaushik M; Parveen S; Tabassum H; Parvez S
Mol Neurobiol; 2020 Dec; 57(12):4921-4928. PubMed ID: 32813238
[TBL] [Abstract][Full Text] [Related]
7. Kawasaki-like disease in children with COVID-19: A hypothesis.
Amirfakhryan H
Med Hypotheses; 2020 Oct; 143():110117. PubMed ID: 32721809
[TBL] [Abstract][Full Text] [Related]
8. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.
Danser AHJ; Epstein M; Batlle D
Hypertension; 2020 Jun; 75(6):1382-1385. PubMed ID: 32208987
[TBL] [Abstract][Full Text] [Related]
9. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
Huang Y; Xie C; Chen X; Hong Q; Huang H
Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
[No Abstract] [Full Text] [Related]
10. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.
Gheblawi M; Wang K; Viveiros A; Nguyen Q; Zhong JC; Turner AJ; Raizada MK; Grant MB; Oudit GY
Circ Res; 2020 May; 126(10):1456-1474. PubMed ID: 32264791
[TBL] [Abstract][Full Text] [Related]
11. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 and androgen-targeted therapy for prostate cancer patients.
Bhowmick NA; Oft J; Dorff T; Pal S; Agarwal N; Figlin RA; Posadas EM; Freedland SJ; Gong J
Endocr Relat Cancer; 2020 Sep; 27(9):R281-R292. PubMed ID: 32508311
[TBL] [Abstract][Full Text] [Related]
13. Severe COVID-19: what have we learned with the immunopathogenesis?
Bordallo B; Bellas M; Cortez AF; Vieira M; Pinheiro M
Adv Rheumatol; 2020 Sep; 60(1):50. PubMed ID: 32962761
[TBL] [Abstract][Full Text] [Related]
14. An Insight into the Sex Differences in COVID-19 Patients: What are the Possible Causes?
Maleki Dana P; Sadoughi F; Hallajzadeh J; Asemi Z; Mansournia MA; Yousefi B; Momen-Heravi M
Prehosp Disaster Med; 2020 Aug; 35(4):438-441. PubMed ID: 32600476
[TBL] [Abstract][Full Text] [Related]
15. Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes.
Debnath M; Banerjee M; Berk M
FASEB J; 2020 Jul; 34(7):8787-8795. PubMed ID: 32525600
[TBL] [Abstract][Full Text] [Related]
16. The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions.
Behl T; Kaur I; Bungau S; Kumar A; Uddin MS; Kumar C; Pal G; Sahil ; Shrivastava K; Zengin G; Arora S
Life Sci; 2020 Sep; 257():118075. PubMed ID: 32653522
[TBL] [Abstract][Full Text] [Related]
17. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm.
Garvin MR; Alvarez C; Miller JI; Prates ET; Walker AM; Amos BK; Mast AE; Justice A; Aronow B; Jacobson D
Elife; 2020 Jul; 9():. PubMed ID: 32633718
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 and the Heart.
Akhmerov A; Marbán E
Circ Res; 2020 May; 126(10):1443-1455. PubMed ID: 32252591
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Datta PK; Liu F; Fischer T; Rappaport J; Qin X
Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
[TBL] [Abstract][Full Text] [Related]
20. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]